Journal
CLINICAL PHARMACOKINETICS
Volume 58, Issue 7, Pages 859-874Publisher
ADIS INT LTD
DOI: 10.1007/s40262-019-00742-8
Keywords
-
Categories
Funding
- ZonMw 'Goed Gebruik Geneesmiddelen' [836031008]
- Dutch Kidney Foundation [13OI116]
Ask authors/readers for more resources
Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available